Department of Endocrinology, The Children's Hospital of Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China.
World J Gastroenterol. 2011 Feb 14;17(6):735-42. doi: 10.3748/wjg.v17.i6.735.
To investigate if non-alcoholic fatty liver disease (NAFLD) is an early mediator for prediction of metabolic syndrome, and if liver B-ultrasound can be used for its diagnosis.
We classified 861 obese children (6-16 years old) into three subgroups: group 0 (normal liver in ultrasound and normal transaminases); group 1 (fatty liver in ultrasound and normal transaminases); and group 2 (fatty liver in ultrasound and elevated transaminases). We measured the body mass index, waist and hip circumference, blood pressure, fasting blood glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), whole-body insulin sensitivity index (WBISI), lipid profile and transaminases in all the participants. The risk of developing metabolic syndrome (MS) was assessed according to the degree of liver fatty infiltration based on the B-ultrasound examination.
Among the 861 obese children, 587 (68.18%) were classified as having NAFLD, and 221 (25.67%) as having MS. The prevalence of MS in NAFLD children (groups 1 and 2) was 37.64% (221/587), which was much higher than that in non-NAFLD group (group 0, 12.04%) (P < 0.01). There were significantly higher incidences concerning every component of MS in group 2 compared with group 0 (P < 0.05). The incidence of NAFLD in MS patients was 84.61% (187/221), which was significantly higher than that of hypertension (57.46%, 127/221) and glucose metabolic anomalies (22.62%, 50/221), and almost equal to the prevalence of dyslipidemia (89.14%, 197/221). Based on the B-ultrasound scales, the presence of moderate and severe liver fatty infiltration carried a high risk of hypertension [odds ratio (OR): 2.18, 95% confidence interval (95% CI): 1.27-3.75], dyslipidemia (OR: 7.99, 95% CI: 4.34-14.73), impaired fasting glucose (OR: 3.65, 95% CI: 1.04-12.85), and whole MS (OR: 3.77; 95% CI: 1.90-7.47, P < 0.01). The state of insulin resistance (calculated by HOMA-IR and WBISI) deteriorated as the degree of fatty infiltration increased.
NAFLD is not only a liver disease, but also an early mediator that reflects metabolic disorder, and liver B-ultrasound can be a useful tool for MS screening.
探讨非酒精性脂肪性肝病(NAFLD)是否为预测代谢综合征的早期中介,以及肝脏 B 超是否可用于其诊断。
我们将 861 例肥胖儿童(6-16 岁)分为三组:组 0(超声正常和转氨酶正常);组 1(超声脂肪肝和转氨酶正常);组 2(超声脂肪肝和转氨酶升高)。我们测量了所有参与者的体重指数、腰围和臀围、血压、空腹血糖、胰岛素、稳态模型评估的胰岛素抵抗(HOMA-IR)、全身胰岛素敏感性指数(WBISI)、血脂谱和转氨酶。根据 B 超检查肝脏脂肪浸润程度评估代谢综合征(MS)的发病风险。
在 861 例肥胖儿童中,587 例(68.18%)被归类为患有 NAFLD,221 例(25.67%)患有 MS。NAFLD 儿童(组 1 和 2)的 MS 患病率为 37.64%(221/587),明显高于非 NAFLD 组(组 0,12.04%)(P <0.01)。与组 0 相比,组 2 中 MS 的每个成分的发生率均明显更高(P <0.05)。MS 患者中 NAFLD 的发生率为 84.61%(187/221),明显高于高血压(57.46%,127/221)和葡萄糖代谢异常(22.62%,50/221),几乎与血脂异常的发生率(89.14%,197/221)相等。基于 B 超分级,中度和重度肝脂肪浸润的存在与高血压(比值比[OR]:2.18,95%置信区间[95%CI]:1.27-3.75)、血脂异常(OR:7.99,95%CI:4.34-14.73)、空腹血糖受损(OR:3.65,95%CI:1.04-12.85)和整个 MS(OR:3.77;95%CI:1.90-7.47,P <0.01)的高风险相关。随着脂肪浸润程度的增加,胰岛素抵抗状态(通过 HOMA-IR 和 WBISI 计算)恶化。
NAFLD 不仅是一种肝脏疾病,还是反映代谢紊乱的早期中介,肝脏 B 超可作为 MS 筛查的有用工具。